Clinical Trials in Joondalup, Western Australia
8 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S1,280 enrolled285 locationsNCT07207811
Recruiting
Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled337 locationsNCT06875310
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Ulcerative Colitis (UC)
Xencor, Inc.270 enrolled40 locationsNCT06619990
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled564 locationsNCT07037459
Recruiting
Phase 1Phase 2
Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Mild to Moderate Asthma
Prana Therapies Inc96 enrolled2 locationsNCT07245368
Recruiting
Not Applicable
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
Hepatitis C
Kirby Institute6,000 enrolled29 locationsNCT03685045